BOSTON--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (Amex: JAV) announced today plans to present at the UBS Global Life Sciences Conference on Thursday, September 28, 2006 at 1:30 p.m. EDT in Ballroom D at the Grand Hyatt, New York City. Dr. Daniel Carr, M.D., CEO and CMO of Javelin will present a corporate update and discuss positive final results of its US Phase 2B study for its lead product Dyloject(TM), recently reported at “Europe Against Pain”, the 5th Congress of the European Federation of IASP Chapters (EFIC). IASP is the International Association for the Study of Pain, the largest organization worldwide of pain researchers and clinicians. He will also review the progress of the Company’s two other late-stage product candidates, Rylomine(TM) (intranasal morphine) and PMI-150 (intranasal ketamine).
